A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Conditions
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) · Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Clinical Trial Site, New Haven, Connecticut, United States
Clinical Trial Site, Detroit, Michigan, United States
Clinical Trial Site, New Brunswick, New Jersey, United States
Clinical Trial Site, New York, New York, United States
Clinical Trial Site, New York, New York, United States
Clinical Trial Site, Cleveland, Ohio, United States
Clinical Trial Site, Nashville, Tennessee, United States
Clinical Trial Site, Houston, Texas, United States
Clinical Trial Site, Toronto, Ontario, Canada
Clinical Trial Site, Montreal, Quebec, Canada
Clinical Trial Site, Copenhagen, Denmark
Clinical Trial Site, Odense C, Denmark
Clinical Trial Site, El Palmar, Murcia, Spain
Clinical Trial Site, Pamplona, Navarre, Spain
Clinical Trial Site, Barcelona, Spain
Clinical Trial Site, Madrid, Spain
Clinical Trial Site, Salamanca, Spain